Somaxon Pharmaceuticals, Inc. (Somaxon) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The Company is focused on the development of Silenor. Somaxon completed its new drug application (NDA) for Silenor and submitted it to the United States Food and Drug Administration (FDA) on January 31, 2008.